Trimethoprim + Sulphamethoxazole in Urinary Tract Infections: A Double Blind Trial

Abstract

Only a very limited number of double blind studies using trimethoprim-sulphamethoxazole in urinary tract infections have been carried out. In the present double blind trial, TM + SMZ or methacycline were given to two patient groups, each comprising 20 patients. In the TM + SMZ group, 16 patients were cured; in the methacycline group, 11 patients. Between 2 and 6 weeks after the completion of the therapy, 6 pathogenic strains were isolated from the urine specimens in the TM + SMZ group, the corresponding number in the methacycline group being 15. Slight side-effects were observed in 2 patients in the TM + SMZ group; none in the methacycline group. The findings show that TM + SMZ is equal or superior to methacycline in the treatment of urinary tract infections.